Meeting
2018 ASCO Annual Meeting
Phase ib study of trastuzumab emtansine (TDM1) in combination with lapatinib and nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: Stela results.
Authors
Tejal Amar Patel
Methodist Cancer Center, Houston, TX
Tejal Amar Patel , Joe Ensor Jr., Angel Augusto Rodriguez , Anna Belcheva , Jorge German Darcourt , Polly Ann Niravath , John G. Kuhn , Virginia G. Kaklamani , Xiaoxian Li , Toniva Boone , Jenny Chee Ning Chang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT02073916
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1035)
DOI
10.1200/JCO.2018.36.15_suppl.1035
Abstract #
1035
Poster Bd #
116
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase Ib trial of trastuzumab emtansine (TE) in combination with lapatinib (L) plus nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: STELA trial.
First Author: Tejal Amar Patel
Poster
2017 ASCO Annual Meeting
Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study.
First Author: Geoffrey John Lindeman
Poster
2014 ASCO Annual Meeting
Phase I study of BYL719 and trastuzumab-MCC-DM1 (T-DM1) in HER2-positive metastatic breast cancer (MBC) patients with progression on trastuzumab and taxane-based therapy.
First Author: Sarika Jain
Poster
2023 ASCO Annual Meeting
A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer.
First Author: Virginia F. Borges